This study evaluated the ability of MRI-ADCand [68Ga]Ga-PSMA-11-based quantitative analyses to help differentiate low-risk prostate cancer patients (ISUP one) from the higher-risk patient classes (ISUP>1) and aimed to evaluate the benefits of the two imaging techniques combined. The gene discussed is FOLH1; the disease is prostate carcinoma.